Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). [electronic resource]
Producer: 20090825Description: 589-95 p. digitalISSN:- 1573-7217
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Breast Neoplasms -- drug therapy
- Clinical Trials as Topic -- economics
- Cost-Benefit Analysis -- economics
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Docetaxel
- Doxorubicin -- administration & dosage
- Female
- Fluorouracil -- therapeutic use
- Humans
- Korea
- Middle Aged
- Taxoids -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.